Jade Biosciences Doses First Patient in Phase 1 Trial for Novel Antibody Jade201
JBIO has more than doubled off its 52-week low of $6.565.
Summary
Jade Biosciences has dosed the first participant in its first-in-human Phase 1 clinical trial for Jade201, a novel anti-BAFF receptor monoclonal antibody. This marks a critical step in advancing the company's pipeline from preclinical to human testing. The news follows recent Q1 2026 disclosures of increased losses and significant capital raising efforts, including a $200 million ATM offering and a $600 million universal shelf registration. Progress in the clinical pipeline is crucial for investor confidence given the company's financial position. Interim Phase 1 data for Jade201 is expected in 2027.
At the time of this announcement, JBIO was trading at $21.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $6.57 to $28.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.